Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Virginia: - Inova Schar Cancer Institute — Fairfax, Virginia
- Inova Fairfax Hospital — Falls Church, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- Inova Fairfax Hospital — Falls Church, Virginia
- Children's Hospital of The King's Daughters — Norfolk, Virginia
- Naval Medical Center - Portsmouth — Portsmouth, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 3 Recruiting Academic/Other
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05976763
Sites in Virginia: - VCU Massey Cancer Center at Stony Point — Richmond, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 3 Recruiting Network
This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. U…
Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT06724237
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of geriatric evaluation and management with survivorship health education (GEM-S) to usual care on patient-reported physical function in older survivors of cancer. Survivorship care for older adults…
Sponsor: University of Rochester
NCT ID: NCT05006482
Sites in Virginia: - Chesapeake Regional Medical Center — Chesapeake, Virginia
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Virginia: - University of Virginia Cancer Center ( Site 0040) — Charlottesville, Virginia
- Inova Schar Cancer Institute ( Site 0015) — Fairfax, Virginia
- Virginia Commonwealth University (VCU) Medical Center ( Site 0030) — Richmond, Virginia
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of son…
Sponsor: BeOne Medicines
NCT ID: NCT06742996
Sites in Virginia: - University of Virginia — Charlottesville, Virginia
- Virgina Cancer Specialists — Gainesville, Virginia
- Vcu Massey Cancer Center — Richmond, Virginia
Phase 3 Recruiting Industry
The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymph…
Sponsor: Celgene
NCT ID: NCT06911502
Sites in Virginia: - Local Institution - 0238 — Fairfax, Virginia
- Hematology Oncology Associates of Fredericksburg — Fredericksburg, Virginia
- Blue Ridge Cancer Care — Roanoke, Virginia
Phase 2, Phase 3 Recruiting Industry
The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05139017
Sites in Virginia: - Blue Ridge Cancer Care ( Site 0169) — Roanoke, Virginia
Phase 3 Recruiting Industry
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be m…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06091254
Sites in Virginia: - University of Virginia — Charlottesville, Virginia
- Virginia Commonwealth University — Richmond, Virginia
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refracto…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06084936
Sites in Virginia: - University of Virginia — Charlottesville, Virginia
Phase 3 Recruiting Industry
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Sites in Virginia: - Virginia Cancer Institute — Richmond, Virginia
Phase 2 Recruiting Network
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (ref…
Sponsor: Children's Oncology Group
NCT ID: NCT02981628
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- Inova Fairfax Hospital — Falls Church, Virginia
- Children's Hospital of The King's Daughters — Norfolk, Virginia
Phase 2 Recruiting NIH
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- Inova Fairfax Hospital — Falls Church, Virginia
- Children's Hospital of The King's Daughters — Norfolk, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
- Carilion Children's — Roanoke, Virginia
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- Children's Hospital of The King's Daughters — Norfolk, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
- Carilion Children's — Roanoke, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD…
Sponsor: Lyell Immunopharma, Inc.
NCT ID: NCT05826535
Sites in Virginia: - Virginia Oncology Associates — Norfolk, Virginia
- Virginia Commonwealth University-Massey Cancer Center — Richmond, Virginia
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse ev…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05963074
Sites in Virginia: - Virginia Cancer Specialists — Manassas, Virginia
- Virginia Oncology Associates — Virginia Beach, Virginia
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia …
Sponsor: Tanja Andrea Gruber
NCT ID: NCT05848687
Sites in Virginia: - Children's Hospital of The King's Daughters — Norfolk, Virginia
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.
Sponsor: Kite, A Gilead Company
NCT ID: NCT04989803
Sites in Virginia: - Virginia Oncology Associates — Norfolk, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymph…
Sponsor: Dren Bio
NCT ID: NCT05475925
Sites in Virginia: - Dren Investigational Site — Charlottesville, Virginia
- Dren Investigational Site — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in participants with R/R B ALL who have recei…
Sponsor: AstraZeneca
NCT ID: NCT06137118
Sites in Virginia: - Research Site — Richmond, Virginia
Phase 2 Recruiting Academic/Other
This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete resp…
Sponsor: Providence Health & Services
NCT ID: NCT06175000
Sites in Virginia: - University of Virginia — Charlottesville, Virginia
Phase 2 Recruiting Industry
This is an open-label, phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell Lymphoma (CT…
Sponsor: Prescient Therapeutics, Ltd.
NCT ID: NCT06854653
Sites in Virginia: - Virginia Commonwealth University Massey Comprehensive Cancer Cente — Richmond, Virginia
Phase 2 Recruiting Academic/Other
Subjects with relapsed large cell lymphoma will receive 3 cycles of combination therapy consisting of GDP and epcoritamab. Each cycle will last 21 days. GDP consists of gemcitabine 1000 mg/m2 IV on Days 1 and 8, cisplatin 75 mg/m2 IV on Da…
Sponsor: Dipenkumar Modi
NCT ID: NCT05852717
Sites in Virginia: - University of Virginia Health System — Charlottesville, Virginia
Phase 1 Recruiting Industry
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or rec…
Sponsor: ADC Therapeutics S.A.
NCT ID: NCT04970901
Sites in Virginia: - Emily Couric Clinical Cancer Center — Charlottesville, Virginia
- NEXT Virginia (Virginia Cancer Specialists) — Fairfax, Virginia